LY-364947
Catalog Number : 3965362
description
LY-364947 is a selective inhibitor of transforming growth factor beta pathway and suppresses TGF-Beta dependent growth in the relevant cell lines. It is also reported to inhibit MDA-MB-231 breast cancer cells in a matrigel invasion assay and block chondrogenesis in human stem cells.
Additional Information
Applications:
|
FA
|
Synonyms:
|
TbetaR-I Inhibitor, LY364947, LY 364947, Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor
|
Formulation:
|
Crystalline solid
|
Chemical Name:
|
4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline
|
Molecular Formula:
|
C17H12N4 |
Molecular Weight: |
272.3
|
CAS Number
|
396129-53-6
|
Purity:
|
≥98%
|
Storage Conditions:
|
Product should be kept at -20°C.
|
References:
|
S Bansal, S., Celia, C., Ferrati, S., Zabre, E., Ferrari, M., Palapattu, G., & Grattoni, A. (2013). Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations. Current drug targets,14(9), 1061-1069. Nassar, K., Tura, A., Lueke, J., Lueke, M., & Grisanti, S. (2012). The novel use of LY364947 (LY), a TGF-ß Type I receptor inhibitor, in prevention of proliferative vitreoretinopathy (PVR). Investigative Ophthalmology & Visual Science, 53(14), 893-893. Oka, M., Iwata, C., Suzuki, H. I., Kiyono, K., Morishita, Y., Watabe, T., ... & Miyazono, K. (2008). Inhibition of endogenous TGF-β signaling enhances lymphangiogenesis. Blood, 111(9), 4571-4579. |